Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000002856
- Lead Sponsor
- Devision of Clinical Oncology, Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. active double cancer(s) 2. undertook radiation therapy for abdominal lesions. 3. HIV-positive patients 4. sever comorbidity (intestinal obstruction, uncontrolled Diabetes M., uncontrolled hypertension, Angina P., liver cirrhosis, pneumonitis, emphysema, etc) 5. allergy for TS1 6. ascites or pleural effusion that needs to be treated 7. patients with bleeding 8. patients treated with fruitosin 9. pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method